FOSL1, along with the cognate transcript and protein product, represents a highly promising therapeutic target in a wide range of aggressive tumors, in which Fra-1-controls the key hallmarks of tumor progression, including cancer cell proliferation, EMT, gain of stem-like features, anoikis resistance, and metastasis. Here, FOSL1 is linked to neoplasm.